This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these patients.

This study investigated the effectiveness and safety of panitumumab (Vectibix) when added to maintenance therapy with fluorouracil (Adrucil) and folinic acid (Leucovirin) (FU/FA) in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with FU/FA plus panitumumab was safe and effective for these patients.

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

This study reviewed the current minimally invasive surgical (MIS) approaches for the treatment of patients with rectal cancer (RC).

This study evaluated the best approach for treating lateral lymph node (LLNs) metastasis in patients with locally advanced rectal cancer (LARC). The data showed that a radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates in these patients.

This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple skincare regimen significantly reduced the skin-related side effects associated with panitumumab for these patients.

This study investigated the effectiveness and safety of bevacizumab (Avastin) administered either on the same day or a few days before chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab administered 4 days before chemotherapy significantly improved overall survival with fewer side effects than on the same day.

This study evaluated the effectiveness and safety of regorafenib (Stivarga) versus TAS-102 (Lonsurf; trifluridine-tipiracil) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that both treatments were safe and lead to similar survival outcomes for primary and secondary treatment of patients with unresponsive mCRC.

This study evaluated the short- and long-term outcomes of laparoscopic surgery (LS; keyhole surgery) for the treatment of elderly patients with colorectal cancer (CRC) aged over 80 years. The data showed that LS is a good and safe option for these patients.

This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients.